Lusefi

Monotherapy when diet & exercise alone do not provide adequate glycemic control in adults whom metformin is considered inappropriate due to intolerance. Add-on combination therapy w/ glucose-lowering medicinal products including insulin prep in adults w/ type 2 DM to improve glycemic control when diet & exercise + monotherapy does not provide adequate glycemic control.

2.5 mg once daily, may be increased to 5 mg once daily to achieve sufficient effect.

May be taken with or without food: Take before or after breakfast.

Hypersensitivity. Patients w/ severe ketosis, diabetic coma or pre-coma; severe infection, those who underwent or are scheduled for surgeries, w/ serious trauma.

Discontinue use if ketoacidosis occurs. Increased risk of hypoglycemia. Pituitary dysfunction or adrenal insufficiency; UTI, genital infection; diabetes-like symptoms eg, impaired glucose tolerance & +ve urinary glucose; presence or absence of infections; hypovolemia; dysuria, anuria, oliguria or urinary retention. Poor nutritional status, starvation, irregular diet, insufficient dietary intake or debility; strenuous muscular exercise; excessive wt loss. Ensure adequate hydration during treatment. Periodically check plasma glucose, renal function & other parameters during treatment. Excessive alcohol consumption. Concomitant use w/ sulfonylureas, insulin prep, diuretics or GLP-1 receptor agonists. May affect ability to drive & use machines. Not to be administered in severe renal impairment or end-stage renal failure being treated by dialysis (eGFR 15-29 mL/min/1.73 m²). Severe hepatic dysfunction. Not to be used in women of childbearing potential or during pregnancy. Avoid use during lactation. Childn <20 yr. Elderly.

Cystitis; constipation; pollakiuria; increased blood ketone body & urine β₂-microglobulin, +ve WBC & albumin in urine.

Enhanced hypoglycemic action w/ antidiabetic drugs eg, sulfonylureas, biguanides, thiazolidinediones, DPP-4 & α-glucosidase inhibitors, glinides, GLP-1 receptor agonists, insulin prep; β-blockers, salicylic acids, MAOIs, fibrates. Weakened hypoglycemic action by adrenaline, corticosteroid, thyroid hormone. Enhanced diuretic action w/ loop & thiazide diuretics. Positive urinary glucose & decreased serum 1,5-anhydroglucitol.

Antidiabetic Agents

A10BK07 - luseogliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.

B